Mold-Tek Packaging Ltd

- No explicit mention of any current or planned fundraising through debt or equity in the transcript provided. - The company has been making significant investments via internal accruals and CAPEX, with current year CAPEX expected around Rs. 85-90 crores, possibly reaching Rs. 100 crores by year-end. - Expansion and capacity additions, including pharma and printing facilities, are funded through these investments. - No direct references to issuing new debt or equity for funding were discussed during the Q2 FY25 call. - The focus is on capacity ramp-up, especially in pharma and IML printing, to drive future growth rather than external fundraising.

- Current year FY25 CAPEX expected around Rs. 85-90 crores, higher than the initial Rs. 60 crores estimate due to additional printing and die-cutting machines. - Pharma segment CAPEX around Rs. 34 crores this year, forming part of the overall Rs. 90-100 crores investment including pharma molds and machines. - Pharma investment since last 2 years totals approximately Rs. 90 crores; total investment expected to be close to Rs. 100 crores by end of this year. - FY26 CAPEX guidance tentative: expected to be around Rs. 50-60 crores, lower than current year as no greenfield projects planned; final commentary closer to year-end. - Major upcoming capacity expansion includes 60-70% increase in IML printing capacity by January-February FY26, fully operational by April. - Expansion underway at Panipat, Cheyyar, and Mahad plants to meet growing demand, especially from Aditya Birla Group.

- H2 FY25 expected to be better than H1 due to all plants being operational and pharma contribution increasing from Q3-Q4. - Pharma segment projected to grow significantly with Rs. 30-50 crores revenue expected in FY25 and Rs. 60 crores+ capacity potential. - FY27 revenue expected to exceed Rs. 1000 crores. - Paint segment volume growth expected at 12-15% from next year, improving from 7-8% this year. - Qpack segment showing strong growth (around 14.53% contribution). - Printing capacity to increase by 60-70% by early FY26, aiding higher sales. - EBITDA margins expected to improve with better capacity utilization. - Asset turnover ratio expected to improve to around 2.5 from below 2 currently. - Pharma capacity utilization projected to reach 50%+ in FY26. - Food & FMCG segment expected to see double-digit growth once new facilities are fully operational.

- H2 expected to be better than H1 in topline due to all plants running and pharma contributions increasing from Q3 and Q4 (Rs. 3-6 crores added). - EBITDA margins expected to stabilize and improve as capacity utilization increases and new printing capacities come online by Jan-April. - Volume growth guidance for FY25 is double-digit, approx. 10-15%, driven by paint segment and pharma ramp-up. - Pharma segment revenues targeted to grow from Rs. 30-35 crores in FY25 to up to Rs. 50-60 crores, with long-term opportunity of Rs. 100+ crores based on market penetration. - EBITDA per kg aims to reach Rs. 40-42 by Q1 FY26. - CAPEX for FY26 likely in Rs. 50-60 crores range, focused on expanding printing and pharma capabilities, no greenfield projects expected. - Overall optimism for continuous improvement in bottom line and potential to exceed Rs. 1000 crores revenue by FY27.

- Current orderbook specifics are not explicitly detailed in the transcript. - Pharma segment: Several orders initiated with 6-7 companies testing products, and 3-4 already giving repeat orders. - A major order was recently received from Marksans; new product development underway with possible launches from December/January. - Capacity is ramping up with pharma orders expected to contribute Rs. 3 crores in Q3 and Rs. 4-6 crores in Q4. - Printing capacity expansion (IML) planned to increase capacity by 60%-70% by January-April next year to support order growth. - Pharma commercial supplies anticipated to start from Q4, with estimated pharma revenues potentially reaching Rs. 30-60 crores next financial year. - Existing clients in pharma include Marksans, MSN Labs, Graviti, Pulse, Alkem; several other pharma companies’ audits and approvals underway. - Other segments (paint, lubes) maintain ongoing orders; paint segment demand improving with capacity expansions at Panipat, Cheyyar, and Mahad plants.